Royalty Pharma plc
NASDAQ: RPRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Pablo Legorreta
- Employees
- 100
- Headquarters
- New York, United States
- IPO year
- 2020
- Market cap
- $24.0B
- Website
- https://www.royaltypharma.com
Loading RPRX…
Loading profile data…Frequently asked questions about RPRX
What does Royalty Pharma plc (RPRX) do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neu...
Where does RPRX trade?
Royalty Pharma plc (RPRX) trades on the NASDAQ.
What sector is RPRX in?
Royalty Pharma plc (RPRX) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Royalty Pharma plc?
Pablo Legorreta is the chief executive officer of Royalty Pharma plc (RPRX).
Where is Royalty Pharma plc headquartered?
Royalty Pharma plc is headquartered in United States.
Does RPRX pay a dividend?
Yes — Royalty Pharma plc (RPRX) paid a trailing twelve-month dividend of USD 0.91 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did RPRX go public?
Royalty Pharma plc (RPRX) completed its initial public offering in 2020.